CC
DICE

Casdin Capital’s DICE Therapeutics, Inc. Common Stock DICE Stock Holding History

Casdin Capital’s Portfolio DICE Stock Details DICE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-310,000
Closed -$8.88M – 45
2023
Q1 		$8.88M Buy
310,000
+145,000
+88% +$4.29M 0.73% 31
2022
Q4 		$5.15M Buy
+165,000
New +$5.38M 0.4% 35

Other funds holding DICE

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

Casdin Capital's DICE Position: Q2 2023 in Review

Casdin Capital sold out of DICE Therapeutics, Inc. Common Stock (DICE) in Q2 2023, closing a stake of 310,000 shares — an estimated $8.88M sold.

Casdin Capital first reported a position in DICE in Q4 2022 and held it in 2 quarters. The position peaked at $8.88M in Q1 2023. 160 funds tracked by Wall St. Rank hold DICE as of Q2 2023.

  • Casdin Capital reported no remaining DICE Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Casdin Capital sold 310,000 DICE Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $8.88M.
  • Casdin Capital first reported a position in DICE Therapeutics, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
  • Casdin Capital's DICE Therapeutics, Inc. Common Stock position peaked at $8.88M in Q1 2023.
  • 160 funds tracked by Wall St. Rank held DICE Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Casdin Capital's 13F filing for Q2 2023, filed 14 Aug 2023.